相关实验视频

Updated: May 10, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

使用多模式数据预测I阶段表皮生长因子受体突变的非小细胞肺癌的复发

Akiko Tateishi¹, Hidehito Horinouchi², Nobuji Kouno³

¹National Cancer Center Hospital, Department of Thoracic Oncology, 5-1-1 Tsukiji, Chuo-Ku, Tokyo 104-0045, Japan; National Cancer Center Research Institute, Division of Genome Biology, 5-1-1 Tsukiji, Chuo-Ku, Tokyo 104-0045, Japan.

Lung cancer (Amsterdam, Netherlands)

|August 28, 2025

概括

开发表皮生长因子受体 (EGFR) 突变非小细胞肺癌 (NSCLC) 的综合模型至关重要. 整合临床,放射和TP53突变数据可以提高I期NSCLC复发预测的准确性.

科学领域:

癌症学
遗传学
放射学

背景情况:

对于第一阶段EGFR突变非小细胞肺癌 (NSCLC) 缺乏综合复发预测模型.
现有的模型不能有效地结合临床,成像和遗传数据.
这项研究解决了早期NSCLC综合预后工具的需求.

研究的目的:

开发和验证EGFR突变的第一阶段NSCLC综合复发预测模型.
评估结合临床,放射和全外体测序 (WES) 数据的模型的预测性能.
确定包括基因突变在内的关键因素,以提高预后准确性.

主要方法:

总共有306名EGFR突变NSCLC患者被分为训练 (n=206) 和验证 (n=100) 队列.
考克斯比例危险模型整合了临床,放射和WES衍生的多基因和突变数据.
使用一致性指数 (C指数),时间依赖的AUC和生存分析来评估模型的性能.

主要成果:

确定了三个最佳模型,其中包含TP53突变的临床放射学模型 (模型 39) 显示出最佳性能 (C指数=0. 73).
模型39预测60个月无复发生存率为57. 1% (高风险) 和87. 1% (低风险) (HR=4. 79).
临床放射学模型 (模型 17) 显示60个月RFS率为59. 1% (高风险) 和83. 2% (低风险) (HR=3. 47).

结论:

临床和放射性因素是第一阶段EGFR突变NSCLC复发的有效预测因素.
纳入TP53突变数据显著提高了复发预测模型的预后准确性.
开发的模型为早期NSCLC患者提供了更好的风险分层.

关键词:

没有疾病的生存率发生EGFR突变预测复发情况没有复发的生存率发生TP53突变

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...